Navigation Links
New study finds barriers to pain treatment in children with sickle cell disease
Date:12/6/2009

A new study by researchers from the Medical College of Wisconsin, in Milwaukee, found a substantial variation in hydroxyurea utilization for pain and other sickle cell disease complications in children. Barriers to its use on the part of both providers and patients were also identified. The study led by Amanda M. Brandow, DO, MS, assistant professor of pediatrics at the Medical College and Children's Research Institute at the Children's Hospital of Wisconsin, will be presented at the American Society of Hematology meeting Dec. 7, 2009, in New Orleans.

The study was funded by the National Heart Lung and Blood Institute of the National Institutes of Health. Dr. Brandow is an NIH sickle cell scholar.

Sickle cell disease is often marked by episodes of severe and incapacitating pain called vaso-occlusive painful events, which can sometimes require hospitalization. Hydroxyurea, an oral drug that is most commonly taken once daily, was approved by the U.S. Food and Drug Administration for use in sickle cell disease patients in 1998. While hydroxyurea remains the standard of care for reducing these painful events in adults, little is known about its practice patterns in children.

The researchers surveyed members of the American Society of Pediatric Hematology/Oncology about their practices and patients to evaluate patterns and barriers to hydroxyurea use. Of the 1,128 surveys disseminated, 31 percent (350 surveys) were returned.

To standardize and increase the quality of care for both adults and children with sickle cell disease, the National Heart, Lung, and Blood Institute (NHLBI) provides clinical practice guidelines for the management of this blood disorder. Most of the survey respondents had heard of (87 percent) and read (78 percent) these guidelines, and provider utilization of hydroxyurea correlated with awareness of the NHLBI recommendations.

The survey found that only eight percent of providers had half or mo
'/>"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-955-4700
Medical College of Wisconsin
Source:Eurekalert

Page: 1 2

Related medicine news :

1. BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors Informational and Educational Use
2. News brief -- childhood cancer survivor study report: Late recurrence is a risk for some cancers
3. Muscle cell infusion shown to strengthen sphincters in animals in Stanford study
4. Congress Has Allowed Most Previous Medicare Cuts to Take Effect, New Study Shows
5. NYU Langone Medical Center Study Shows VNS Therapy is a Safe and Effective Treatment for Refractory Epilepsy
6. Diabetes Drugs Go Head-to-Head in Study
7. Cell Phone Text Messaging Technology is a Low-Cost, Effective Way to Improve Use of Sunscreen and Reduce Risk of Skin Cancer, According to a New Study
8. Personality predicts success in medical school, says new study by U of Minnesota professor
9. Teen Internet Addicts More Likely to Self-Harm: Study
10. Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care
11. New Study Confirms Health Benefits of Pecorino Romano Cheese
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... entered into an agreement with one of the ... drug candidates for the detection and treatment of ... novel antibody discovery and Roche,s expertise in developing ... possibility of improved treatment for cancer, a leading ... makes use of BTI,s discovery of a new ...
(Date:7/14/2014)... Florida (PRWEB) July 14, 2014 Botanica ... Open House event will be held at the day ... July 16th from 4-8pm. Wine and other refreshments will ... of retail discounts on beauty products and ... treatment known as dermaplaning. , Dermaplaning (also known ...
(Date:7/14/2014)... Barbara Bronson Gray ... (HealthDay News) -- New research suggests that a faltering ... Alzheimer,s disease, and that an inexpensive, low-tech smell test ... In two different studies, the decreased ability to ... cell function and progression to Alzheimer,s disease. "We,re ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 (HealthDay ... have bigger brains and sharper thinking skills than their peers, ... between playing games such as puzzles, crosswords, cards and checkers ... Researchers found that people who played those games at ... and other mental functions. And, based on MRI scans, they ...
(Date:7/14/2014)... Atlanta, GA (PRWEB) July 14, 2014 ... networking and relationship-marketing firm, announced today that nominations ... for the 2014 Information Security Executive® (ISE®) North ... Security Executive® of the Year, which recognizes executives ... organizations through risk management, data-asset protection, regulatory compliance, ...
Breaking Medicine News(10 mins):Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3
... liver disease (NAFLD) is the most common cause of ... for patients with NAFLD is currently available//. Understanding the ... patients with NAFLD is important for patient counseling as ... ,To deal with these issues, researchers from Mayo Clinic ...
... genetically modified mosquito has been created that wipe out natural ... of the world such as India and South Asia. ... the wild in an attempt to combat malaria that is ... ,A similar attempt was made in India in 1970s ...
... to start its Phase III cancer vaccine trial against ... is the new skin cancer vaccine developed by Antigenics.// ... 322 patients failed to meet the required statistically significance ... was not shown to have any better results compared ...
... news for adults with acne and resultant facial scarring. ... Surgery, the medical journal of the American Society for ... - or non-ablative - lasers showed significant improvement of ... common with ablative procedures, such as facial resurfacing, dermabrasion ...
... survival rate of women with breast cancer has increased by ... years//. The experts feel that the increase in breast cancer ... detection of breast cancer and also due to more effective ... of cancer. ,Professor Michel Coleman, Epidemiologist, Cancer Research ...
... found that it is better to insert drug-coated stents ... who have diabetes//. ,The study author Dr. ... University Hospital in Madrid said that the results of ... have poorer prognosis as compared to non-diabetics after angioplasty. ...
Cached Medicine News:Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2Health News:Breast cancer women has shown an increase in survival rates 2
(Date:7/14/2014)... Lumin Medical LLC, a healthcare IT provider, ... leading provider of on-demand patient tracking solutions and is ... to Franklin, Wis. ... and our mission is to provide visibility for the ... reduce costs," said James Hermann , President of ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... EAGAN, Minn. , July 14, 2014  Today, ... Partners, announced that it acquired the assets of MicroTest ... MA.  The acquisition of MTL is the first step ... and chemistry laboratory services platform to support the medical ... be known as Accuratus Lab Services , a ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3
... III Study for the Treatment of Advanced Prostate CancerPARSIPPANY, ... launch of a Phase IIIB clinical trial of degarelix ... antagonist approved by the U.S. Food and Drug Administration ... cancer. The announcement was made at ...
... Diagnostic ToolSUNNYVALE, Calif., April 27 Cepheid (Nasdaq: ... MTB/RIF as a CE IVD Mark product under the ... Devices. For the first time, European clinicians will have ... Mycobacterium tuberculosis (MTB) and resistance to rifampicin ...
Cached Medicine Technology:Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: